# OnCo record avc-201 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/avc-201/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "avc-201" ;
  schema:name "AVC-201"@en ;
  schema:alternateName "Allo-RevCAR01-T-CD123"@en, "Allo-RevCAR01-T with R-TM123"@en ;
  schema:description "AVC-201 is an experimental allogeneic CRISPR-engineered switchable CAR-T cell therapy from AvenCell Therapeutics, in phase 1 trials for CD123-positive relapsed/refractory or MRD-positive acute myeloid leukaemia."@en ;
  schema:url <https://onco.cc/drugs/avc-201/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://avencell.com/pipeline/>, <https://avencell.com/avencell-therapeutics-to-report-phase-1a-results-of-first-in-class-switchable-allogeneic-cd123-car-t-therapy-for-aml-in-late-breaking-oral-presentation-at-eha-2026/>, <https://avencell.com/avencell-therapeutics-to-report-phase-1a-results-of-first-in-class-switchable-allogeneic-cd123-car-t-therapy-for-aml-in-late-breaking-oral-presentation-at-eha-2026/>, <https://clinicaltrials.gov/study/NCT05949125>, <https://clinicaltrials.gov/search?intr=AVC-201> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Allogeneic CRISPR-engineered switchable CAR-T cell therapy (RevCAR, with separately dosed targeting module)" ;
  onco:cancers <https://onco.cc/cancers/aml/> ;
  onco:targets <https://onco.cc/targets/cd123/> ;
  onco:companies <https://onco.cc/companies/avencell-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct05949125/> .